A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy as a possible treatment for Smoldering
Multiple Myeloma.
The following intervention will be involved in this study:
- Lenalidomide
- Citarinostat (CC-96241)
- PVX-410